This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
HeadlineMEDTECH

AI Personalized Drug Dosing Engine PharmaMatch Approved by EMA: Customizing Drug Dosages From Genomics to Metabolomics

AI personalized drug dosing engine PharmaMatch, jointly developed by the Royal Dutch Pharmaceutical Association and Tempus AI, gains EMA approval, integrating genomic and metabolomic data to customize optimal drug dosages for each patient.

On December 21, 2029, the European Medicines Agency (EMA) approved the AI personalized drug dosing engine PharmaMatch. Jointly developed by the Royal Dutch Pharmaceutical Association and Tempus AI, the system integrates patient genomic variants, liver metabolic enzyme activity, drug interactions, and real-time blood drug concentration data to calculate optimal drug type and dosage for each patient.

PharmaMatch addresses a problem that has plagued clinical medicine for years: the same drug can have up to 10-fold efficacy differences between patients. Traditional dosing is based on "average weight and kidney function," ignoring individual pharmacogenomic variations.

In clinical trials with warfarin, PharmaMatch-calculated personalized doses reduced bleeding complications from 8.2% to 1.9% while maintaining equivalent anticoagulation efficacy.

PharmaMatch initially supports personalized dosing for 50 commonly used drugs across cardiovascular, oncology, and immunosuppression therapeutic areas. The EMA requires all EU member states to integrate PharmaMatch into electronic prescribing systems by end of 2030.